May 11, 2021
Applied Therapeutics Reports First Quarter 2021 Financial Results
Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency NDA submission for AT-007 in Galactosemia expected no later than Q3 2021; commercial preparations ongoing Completion of enrollment in ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy on track
Apr 07, 2021
Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster presentation at
Mar 16, 2021
Applied Therapeutics to Host Virtual Rare Disease Forum
NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a Virtual
Feb 23, 2021
Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at two
Feb 22, 2021
Applied Therapeutics, Inc. Announces Closing of Public Offering
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the closing
Feb 01, 2021
Applied Therapeutics Announces Restart of Pediatric Galactosemia Study
FDA Clinical Hold Lifted NEW YORK, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced


Print Page
Print Page
Email Alerts
RSS Feeds
RSS Feeds
Contact IR
Contact IR
AP_logo_KO
linkedin
facebook
twitter

©2021 Applied Therapeutics All Rights Reserved

linkedin
facebook
twitter
AP_logo_KO

©2021 Applied Therapeutics All Rights Reserved